Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylan insulin glargine versus Lantus in type 1 diabetes mellitus
2014-000747-32Phase 3Completed
- Sponsor
- Mylan
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Mylan. Primary endpoint: Change in HbA1c from baseline to 24 weeks. Started Jun 2014; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2014-000747-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000747-32.